Low Dose Oral Minoxidil in COVID-19-Associated Telogen Effluvium: A Retrospective Analysis of 69 Patients

    Cesar D. Villarreal-Villareal, Daniela Mares-Custodio, Estefania Boland-Rodríguez, Juan Garza, David Saceda‐Corralo
    Image of study
    TLDR Low-dose oral minoxidil helps hair regrowth in COVID-19-related hair loss with few side effects.
    This retrospective study evaluated the effectiveness of low-dose oral minoxidil (LDOM) in treating COVID-19-associated telogen effluvium (CATE) in 69 patients. The study found that LDOM significantly reduced hair shedding, as measured by the hair-shedding Sinclair score (HSS), over successive visits. The median HSS decreased from 5 at the 2nd visit to 2 at the 4th visit, indicating improved hair growth. The average time for telogen effluvium resolution was 93 days. Despite limitations such as the retrospective design and lack of a control group, the study concludes that LDOM is a beneficial treatment for CATE.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 1000+ results

    Similar Research

    5 / 1000+ results